Logo image of TLT.CA

THERALASE TECHNOLOGIES INC (TLT.CA) Stock Fundamental Analysis

TSX-V:TLT - TSX Venture Exchange - CA88337V1004 - Common Stock - Currency: CAD

0.2  +0.01 (+2.56%)

Fundamental Rating

2

TLT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 2 industry peers in the Health Care Equipment & Supplies industry. TLT has a bad profitability rating. Also its financial health evaluation is rather negative. TLT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TLT had negative earnings in the past year.
In the past year TLT has reported a negative cash flow from operations.
TLT had negative earnings in each of the past 5 years.
TLT had a negative operating cash flow in each of the past 5 years.
TLT.CA Yearly Net Income VS EBIT VS OCF VS FCFTLT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

With a Return On Assets value of -150.75%, TLT perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
With a Return On Equity value of -409.16%, TLT perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
Industry RankSector Rank
ROA -150.75%
ROE -409.16%
ROIC N/A
ROA(3y)-132.13%
ROA(5y)-105.29%
ROE(3y)-205.01%
ROE(5y)-152.63%
ROIC(3y)N/A
ROIC(5y)N/A
TLT.CA Yearly ROA, ROE, ROICTLT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

With a Gross Margin value of 53.23%, TLT perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
In the last couple of years the Gross Margin of TLT has grown nicely.
TLT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.53%
GM growth 5Y53.42%
TLT.CA Yearly Profit, Operating, Gross MarginsTLT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

TLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLT has been increased compared to 1 year ago.
TLT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TLT has been reduced compared to a year ago.
TLT.CA Yearly Shares OutstandingTLT.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
TLT.CA Yearly Total Debt VS Total AssetsTLT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -20.44, we must say that TLT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TLT (-20.44) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.15 indicates that TLT is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.15, TLT is doing good in the industry, outperforming 71.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -20.44
ROIC/WACCN/A
WACC7.72%
TLT.CA Yearly LT Debt VS Equity VS FCFTLT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

TLT has a Current Ratio of 0.82. This is a bad value and indicates that TLT is not financially healthy enough and could expect problems in meeting its short term obligations.
TLT has a Current ratio (0.82) which is comparable to the rest of the industry.
TLT has a Quick Ratio of 0.82. This is a bad value and indicates that TLT is not financially healthy enough and could expect problems in meeting its short term obligations.
TLT has a Quick ratio of 0.52. This is comparable to the rest of the industry: TLT outperforms 42.86% of its industry peers.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.52
TLT.CA Yearly Current Assets VS Current LiabilitesTLT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.54% over the past year.
Looking at the last year, TLT shows a decrease in Revenue. The Revenue has decreased by -8.62% in the last year.
Measured over the past years, TLT shows a small growth in Revenue. The Revenue has been growing by 1.40% on average per year.
EPS 1Y (TTM)7.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.27%
Revenue 1Y (TTM)-8.62%
Revenue growth 3Y9.8%
Revenue growth 5Y1.4%
Sales Q2Q%-47.89%

3.2 Future

The Earnings Per Share is expected to grow by 37.61% on average over the next years. This is a very strong growth
Based on estimates for the next years, TLT will show a very strong growth in Revenue. The Revenue will grow by 256.32% on average per year.
EPS Next Y-21.18%
EPS Next 2Y-34.82%
EPS Next 3Y37.61%
EPS Next 5YN/A
Revenue Next Year17.72%
Revenue Next 2Y93.98%
Revenue Next 3Y256.32%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TLT.CA Yearly Revenue VS EstimatesTLT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
TLT.CA Yearly EPS VS EstimatesTLT.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.01 -0.01 -0.02 -0.03 -0.04

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLT.CA Price Earnings VS Forward Price EarningsTLT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLT.CA Per share dataTLT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02 -0.03

4.3 Compensation for Growth

TLT's earnings are expected to grow with 37.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.82%
EPS Next 3Y37.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERALASE TECHNOLOGIES INC

TSX-V:TLT (6/16/2025, 7:00:00 PM)

0.2

+0.01 (+2.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-28 2025-05-28
Earnings (Next)08-11 2025-08-11
Inst Owners0%
Inst Owner ChangeN/A
Ins Owners2.68%
Ins Owner ChangeN/A
Market Cap49.56M
Analysts84.44
Price Target0.71 (255%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)54.82%
Min Revenue beat(2)-55.73%
Max Revenue beat(2)165.37%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-100%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-48.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 52.21
P/FCF N/A
P/OCF N/A
P/B 45.46
P/tB 45.46
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -150.75%
ROE -409.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.23%
FCFM N/A
ROA(3y)-132.13%
ROA(5y)-105.29%
ROE(3y)-205.01%
ROE(5y)-152.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.53%
GM growth 5Y53.42%
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.08%
Cap/Sales 8.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.82
Quick Ratio 0.52
Altman-Z -20.44
F-Score4
WACC7.72%
ROIC/WACCN/A
Cap/Depr(3y)14.29%
Cap/Depr(5y)27.96%
Cap/Sales(3y)3.87%
Cap/Sales(5y)8.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.27%
EPS Next Y-21.18%
EPS Next 2Y-34.82%
EPS Next 3Y37.61%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.62%
Revenue growth 3Y9.8%
Revenue growth 5Y1.4%
Sales Q2Q%-47.89%
Revenue Next Year17.72%
Revenue Next 2Y93.98%
Revenue Next 3Y256.32%
Revenue Next 5YN/A
EBIT growth 1Y-1.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y48.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.41%
OCF growth 3YN/A
OCF growth 5YN/A